Behavioral nudges lead to striking drop in prescriptions of potent antipsychotic

August 1, 2018, Columbia University's Mailman School of Public Health
Credit: CC0 Public Domain

A study led by Columbia University's Mailman School of Public Health has found that letters targeting high prescribers of Seroquel (quetiapine), an antipsychotic with potentially harmful side effects in the elderly, significantly reduced the number of prescriptions for patients in Medicare. The results showed that peer comparison letters led to statistically meaningful, persistent decreases in quetiapine prescribing, with no detected negative effects on patients. The findings are online in JAMA Psychiatry.

"Compared with existing work on prescribing quality, our study provides a unique example of a large-scale, low-cost intervention yielding clinically meaningful and long-lasting effects," said Adam Sacarny, Ph.D., assistant professor of Health Policy and Management at Columbia's Mailman School of Public Health and first author. The work was conducted with the Office of Evaluation Sciences in the General Services Administration, which promotes evaluation and testing in the federal government; the Centers for Medicare and Medicaid Services, which administers the Medicare program; and researchers at the Harvard T.H. Chan School of Public Health.

The study was a randomized controlled trial targeting the 5,055 highest Seroquel-prescribing nationwide in the Medicare Part D (prescription drug coverage) program in 2013 and 2014. A random half of the doctors were assigned to the treatment arm and received 3 letters comparing their prescribing practices to their peers; the other half received placebo letters about an unrelated Medicare regulation. The treatment arm's letter stated that the physician's prescribing of quetiapine high relative to their peers was under review. The text also discussed that high quetiapine prescribing could be appropriate but was concerning for medically unjustified use. The letter encouraged primary care physicians to review their prescribing patterns.

The physicians who got the peer comparison letters dropped their overall Seroquel prescribing by 11 percent over the next 9 months and 16 percent over the next 2 years. New initiations of Seroquel dropped even more: 24 percent over 2 years.

"Our findings show that for and clinicians aiming to improve the quality of prescribing, peer comparison messages could be useful and effective tools, particularly when they are paired with a review of previous prescribing activity," said Sacarny. "Similar messages could address over-prescribing of other drugs, like opioids, or they could target care that goes against clinical guidelines."

The researchers also followed patients who had been treated by the physicians in the study. On average, patients of the treatment group physicians received 6 percent fewer days of Seroquel from all prescribers over 2 years. Patients with a history of dementia, where guidelines discourage Seroquel prescribing, experienced a larger reduction of 8 percent fewer days of Seroquel. There was no evidence of adverse effects on patients due to the letters: use of the emergency department, hospitalizations, and mortality were similar for patients of treatment and control physicians.

Seroquel is frequently prescribed "off-label", or outside its FDA-approved indications, for with dementia or Alzheimer's disease despite a large body of evidence that it is associated with significant harm in these populations. Guidelines from the American Psychiatric Association and the American Geriatrics Society discourage this overuse of antipsychotics including Seroquel. This off-label use against guidelines has attracted the attention of the Centers for Medicare & Medicaid Services (CMS) and federal oversight agencies.

"Overprescribing of antipsychotic drugs is a huge and persistent problem, particularly in the elderly. We think our results are striking for something as simple and cheap as sending letters," said Dr. Michael Barnett of the Harvard T.H. Chan School of Public Health, the second author on the study. "Beyond the benefit in reducing anti-psychotic use, the intervention could also have implications for how we can nudge physician behavior more broadly."

Sacarny and colleagues showed that with the increasing need to address the dangers of inappropriate prescribing, peer comparison letters targeted at high-risk medications provide one way to efficiently create lasting changes in prescribing patterns.

Explore further: Holding mirror to docs who overprescribe addictive drugs doesn't stem prescriptions

More information: JAMA Psychiatry (2018). DOI: 10.1001/jamapsychiatry.2018.1867

Related Stories

Holding mirror to docs who overprescribe addictive drugs doesn't stem prescriptions

March 7, 2016
Researchers at Columbia University's Mailman School of Public Health, with colleagues at the White House Social and Behavioral Sciences Team, the Massachusetts Institute of Technology, and the Centers for Medicare and Medicaid ...

New rules may constrain docs' ability to treat chronic pain

June 29, 2018
(HealthDay)—New laws and regulations designed to limit the use of prescription narcotics may further constrain doctors' ability to treat patients, according to an article published online May 30 in Medical Economics.

Providing clinicians feedback on their opioid prescribing data alters future prescribing

May 7, 2018
Asking emergency department (ED) providers to self-identify their opioid prescribing practices and then providing them with timely, clinically relevant, individualized, and actionable feedback on their actual opioid prescribing ...

Hundreds of docs have dubious prescribing patterns in part D

June 27, 2013
(HealthDay)—Many hundreds of general-care physicians who order drugs paid for by Medicare Part D have questionable prescribing patterns, according to a report published by the U.S. Department of Health and Human Services ...

Geography matters: Prescribing patterns for opioids in dermatology

February 7, 2018
A new study suggests that opioid prescribing is not widespread among dermatologists, but opportunities exist in concentrated areas to reduce their use. The study appears online Feb. 7 in JAMA Dermatology.

What is Seroquel and should you take it for insomnia?

August 29, 2017
Quetiapine, sold under the brand name Seroquel, is a short-acting antipsychotic drug. It's used to treat schizophrenia, bipolar I disorder and as an add-on treatment for major depression and generalised anxiety disorder in ...

Recommended for you

When scientists push people to their tipping point

December 10, 2018
You probably overestimate just how far someone can push you before you reach your tipping point, new research suggests.

Internet therapy apps reduce depression symptoms, study finds

December 7, 2018
In a sweeping new study, Indiana University psychologists have found that a series of self-guided, internet-based therapy platforms effectively reduce depression.

Gender bias sways how we perceive competence in faces

December 7, 2018
Faces that are seen as competent are also perceived as more masculine, according to research published in Psychological Science, a journal of the Association for Psychological Science.

Targeted cognitive training benefits patients with severe schizophrenia

December 7, 2018
Schizophrenia is among the most difficult mental illnesses to treat, in part because it is characterized by a wide range of dysfunction, from hallucinations and mood disorders to cognitive impairment, especially verbal and ...

Pot withdrawal eased for dependent users

December 6, 2018
A new drug can help people diagnosed with cannabis use disorder reduce withdrawal symptoms and marijuana use, a new Yale-led study published Dec. 6 in the journal Lancet Psychiatry shows.

Link between neonatal vitamin D deficiency and schizophrenia confirmed

December 6, 2018
Newborns with vitamin D deficiency have an increased risk of schizophrenia later in life, a team of Australian and Danish researchers has reported.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.